efinaconazole
Efinaconazole, sold under the brand name Jublia and Clenafin among others, is a triazole antifungal compound discovered by Kaken Pharmaceutical, indicated for the treatment of onychomycosis, a fungal infection of the nail. Since it has low binding affinity with keratin, the main component of nails, it has superior nail-penetrating properties. It is approved for use in the United States, Canada, Japan and certain European countries as a 10% topical solution.
Chemical data
- Formula
- C18H22F2N4O
- Molecular weight
- 348.4 g/mol
- IUPAC name
- (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
via PubChem
Research
281 papers- Efinaconazole in Onychomycosis.American journal of clinical dermatology · 2022
- Efinaconazole.2006
- Efinaconazole and Tavaborole.Journal of pharmacy practice · 2017
- Efinaconazole 10% solution: a comprehensive review of its use in the treatment of onychomycosis.Expert opinion on pharmacotherapy · 2024
- Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients.
Article
6 sectionsContents
- Medical uses
- Efficacy
- History
- Economics
- References
- External links
Efinaconazole, sold under the brand name Jublia and Clenafin among others, is a triazole antifungal compound discovered by Kaken Pharmaceutical, indicated for the treatment of onychomycosis, a fungal infection of the nail. Since it has low binding affinity with keratin, the main component of nails, it has superior nail-penetrating properties. It is approved for use in the United States, Canada, Japan and certain European countries as a 10% topical solution.
Efinaconazole acts as a 14α-demethylase inhibitor.